Dear Patient,
We are writing to you because you currently receive a medicine called Aflibercept (also known by the brand name Eylea®) to treat your eye condition.
Until recently, Aflibercept was made by one pharmaceutical company and supplied as the brand Eylea®. From December 2025, there will be new brands of Aflibercept, known as biosimilars, which will be prescribed by NHS hospitals across the country. Moorfields Eye Hospital will be part of this national programme, and we will be prescribing a biosimilar of Aflibercept rather than Eylea® for our new and existing patients with retinal conditions.
What does this mean for you?
We will be moving to a different supplier of this medication and want to provide some background information on this prior to your next injection visit.
Prior to arriving to your next injection appointment, you will be called by clinician to discuss this change in detail and answer any additional questions to support your understanding as to why this change is being made. They will provide you with all the necessary and important information relating to your injection treatment with biosimilar Aflibercept. There will be an opportunity to discuss any questions you may have. This will help you to make an informed decision prior to signing the consent form for the continuation of your treatment using biosimilar Aflibercept.
The process of administering biosimilar Aflibercept is the same as all the other anti-VEGF intravitreal injections. The injections will continue to be delivered by ophthalmologists, highly trained specialist ophthalmic nurses and practitioners.
We have attached a leaflet with some frequently asked questions which may be of interest to you with this letter. If you have any queries about your treatment, please email moorfields.biosimilars@nhs.net or call 07525 800836.
Thank you.
Kind regards,
Marium Javed
Lead Pharmacist – High-Cost Therapies and Homecare Services
Moorfields Eye Hospital NHS Foundation Trust